Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
AddLife AB ( ($SE:ALIF.B) ) has shared an announcement.
AddLife’s fourth-quarter report shows resilient profitability despite a 3% sales dip, with EBITA margin climbing to 18.2% driven by efficiency gains, portfolio refinements, and two small acquisitions; full-year figures reflect modest 2% net sales growth, 8% higher adjusted EBITA, doubled cash flow, lower leverage, and a proposed dividend hike, indicating a fortified balance sheet ready to restart a more assertive M&A strategy.
The most recent analyst rating on ($SE:ALIF.B) stock is a Hold with a SEK146.00 price target. To see the full list of analyst forecasts on AddLife AB stock, see the SE:ALIF.B Stock Forecast page.
More about AddLife AB
AddLife AB operates in the European labtech and medtech sectors, supplying advanced laboratory instrumentation, diagnostic equipment, and surgical products, with an emphasis on higher-margin proprietary offerings and acquisition-led expansion across healthcare markets.
Average Trading Volume: 132,458
Technical Sentiment Signal: Sell
Current Market Cap: SEK16.63B
Find detailed analytics on ALIF.B stock on TipRanks’ Stock Analysis page.